Business Context and Reporting Period
Company: Gain Therapeutics, Inc. (GANX)
Filing Type: Form 10-Q (Unaudited)
Period Ended: September 30, 2024
Business Overview: Gain Therapeutics is a clinical-stage biotechnology company developing novel small molecule therapeutics for central nervous system (CNS) disorders, lysosomal storage disorders, and metabolic diseases. The company utilizes its proprietary Magellan™ computational platform to identify allosteric binding sites on proteins. Its lead product candidate, GT-02287, is in development for Parkinson's disease.
Key Financial Metrics
| Metric | Q3 2024 (3 Months) | Q3 2023 (3 Months) | YTD 2024 (9 Months) | YTD 2023 (9 Months) |
|---|---|---|---|---|
| Total Revenues | $0 | $0 | $0 | $55,180 |
| Net Loss | $(4,485,692) | $(4,718,263) | $(16,642,964) | $(17,543,551) |
| Loss Per Share (Basic/Diluted) | $(0.17) | $(0.37) | $(0.78) | $(1.42) |
| Cash and Cash Equivalents (Sept 30, 2024) | $12,049,522 | |||
| Total Assets (Sept 30, 2024) | $14,365,664 | |||
| Total Liabilities (Sept 30, 2024) | $5,456,282 | |||
| Accumulated Deficit (Sept 30, 2024) | $(77,426,681) |
Cash Flow (Nine Months Ended Sept 30, 2024):
- Cash used in operating activities: $(15,419,191)
- Cash provided by investing activities: $5,020,954 (primarily maturity of marketable securities)
- Cash provided by financing activities: $10,699,238 (public offering and ATM sales)
Material Changes vs. Prior Period
- Revenue: The company reported $0 revenue for the three and nine months ended September 30, 2024, compared to $55,180 in collaboration revenue for the same period in 2023. The prior year revenue was from a concluded collaboration agreement.
- Operating Expenses:
- Research and Development (R&D): Increased to $2.62 million for Q3 2024 from $2.37 million in Q3 2023. YTD R&D expenses were $9.57 million (2024) vs. $9.15 million (2023). The increase is primarily due to costs associated with the Phase 1 clinical trial of GT-02287.
- General and Administrative (G&A): Decreased to $1.84 million for Q3 2024 from $2.52 million in Q3 2023. YTD G&A expenses were $7.45 million (2024) vs. $8.75 million (2023). The decrease is attributed to reduced legal/professional fees and lower stock-based compensation.
- Financing Activity: In June 2024, the company completed a public offering raising gross proceeds of approximately $11.5 million. Additionally, the company initiated a new At-The-Market (ATM) program in September 2024.
- Foreign Exchange: The company recorded a foreign exchange loss of $121,139 in Q3 2024, compared to a gain of $82,198 in Q3 2023, driven by fluctuations between the Swiss Franc and the US Dollar.
Guidance, Outlook, Risks, and Contingencies
Going Concern: The company has disclosed substantial doubt about its ability to continue as a going concern. Management estimates that existing cash resources ($12 million) will be sufficient to fund operations only until the second quarter of 2025. Additional capital will be required to continue operations beyond this date.
Outlook and Strategy:
- The company is streamlining operational plans to improve capital efficiency.
- Management is actively seeking strategic collaborations, licensing agreements, and grant funding.
- Future financing is expected to come from public/private equity offerings, debt financings, or collaborations.
Risks and Contingencies:
- Legal Proceedings: On September 18, 2024, former CEO Matthias Alder filed litigation alleging breach of the Separation Agreement and employment agreement. The company has accrued $0.53 million for estimated severance benefits related to this matter.
- Nasdaq Compliance: The company received notice in July 2024 regarding non-compliance with the minimum market value of listed securities rule. On October 21, 2024, the company regained compliance.
- Intellectual Property: The company relies on a license from Minoryx Therapeutics S.L. for its core technology. Termination of this license would halt operations.
- Regulatory: Success in early clinical trials (Phase 1) does not guarantee success in later stages. The company must obtain regulatory approval before generating product revenue.
Investor Verification Checklist
- Cash Runway: Verify the timeline for cash exhaustion (projected Q2 2025) and the status of ongoing fundraising efforts.
- Legal Accruals: Monitor the status of the litigation filed by former CEO Matthias Alder and whether the $0.53 million accrual is sufficient.
- Capital Dilution: Review the terms of recent equity offerings (June 2024 public offering and ATM program) and potential future dilution required to extend the runway.
- Clinical Progress: Track the timeline and results of the Phase 1 study for GT-02287 and the planned IND submission for US expansion.
- Nasdaq Listing: Confirm continued compliance with Nasdaq listing requirements, specifically the minimum market value of listed securities.